VivoSeq
Other

Sporotrichosis

3

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Sporotrichosis is an early-stage landscape with 3 programs across 3 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Sebela Pharmaceuticals Development LLC. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

ApprovedS

Sebela Pharmaceuticals Development LLC

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00004938·30 enrolled
Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis
Recruiting·FFirst Hospital of China Medical University·N/A·NCT06300138·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)